Index | S&P Developed Ex-Korea LargeMidCap ESG Enhanced Health Care |
Investment focus | Equity, World, Health Care, Social/Environmental |
Fund size | GBP 52 m |
Total expense ratio | 0.18% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | Yes |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in GBP) | 11.78% |
Inception/ Listing Date | 12 April 2023 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Invesco |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | Invesco Capital Management LLC |
Custodian Bank | BNY Mellon Trust Company (Ireland) Limited |
Revision Company | PricewaterhouseCoopers |
Fiscal Year End | 31 December |
Swiss representative | BNP PARIBAS SECURITIES SERVICES, Paris, succursale de Zurich |
Swiss paying agent | BNP Paribas Securities Services, Paris, succursale de Zurich |
Germany | Unknown |
Switzerland | Unknown |
Austria | Unknown |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | |
Securities lending | No |
Securities lending counterparty |
Eli Lilly & Co. | 10.16% |
UnitedHealth Group | 8.66% |
AbbVie, Inc. | 8.49% |
Novo Nordisk A/S | 4.62% |
Abbott Laboratories | 4.41% |
Roche Holding AG | 4.34% |
Merck & Co., Inc. | 4.18% |
AstraZeneca PLC | 3.76% |
Novartis AG | 3.14% |
Danaher Corp. | 2.79% |
United States | 68.18% |
Switzerland | 8.33% |
Japan | 4.78% |
United Kingdom | 4.49% |
Other | 14.22% |
Health Care | 94.48% |
Consumer Discretionary | 0.68% |
Other | 4.87% |
YTD | +3.52% |
1 month | +3.07% |
3 months | -4.47% |
6 months | -3.49% |
1 year | +3.52% |
3 years | - |
5 years | - |
Since inception (MAX) | +8.05% |
2024 | +3.18% |
2023 | - |
2022 | - |
2021 | - |
Volatility 1 year | 11.78% |
Volatility 3 years | - |
Volatility 5 years | - |
Return per risk 1 year | 0.30 |
Return per risk 3 years | - |
Return per risk 5 years | - |
Maximum drawdown 1 year | -11.98% |
Maximum drawdown 3 years | - |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -11.98% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | WH2E | - - | - - | - |
Borsa Italiana | EUR | WDHE | WDHE IM WHCEINE | WDHE.MI I2PZINAV.DE | Societe Generale |
London Stock Exchange | GBX | WHCG | WHCG LN WHCEINS | WHCG.L I2P0INAV.DE | Societe Generale |
London Stock Exchange | USD | WHCE | WHCE LN WHCEIN | WHCE.L I2P1INAV.DE | Societe Generale |
SIX Swiss Exchange | USD | WHCE | WHCE SW WHCEIN | WHCE.S I2P1INAV.DE | Societe Generale |
XETRA | EUR | WH2E | WH2E GY WHCEINE | WH2E.DE I2PZINAV.DE | Societe Generale |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 1,010 | 0.40% p.a. | Accumulating | Sampling |
iShares Ageing Population UCITS ETF | 365 | 0.40% p.a. | Accumulating | Sampling |
iShares MSCI World Health Care Sector ESG UCITS ETF USD (Acc) | 125 | 0.18% p.a. | Accumulating | Sampling |
Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C | 78 | 0.35% p.a. | Accumulating | Full replication |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 5 | 0.35% p.a. | Accumulating | Full replication |